| Pharmaceutical Information |
| Drug Name |
Carfilzomib |
| Drug ID |
BADD_D00367 |
| Description |
Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy.[L39392] |
| Indications and Usage |
Carfilzomib is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with lenalidomide and dexamethasone; or dexamethasone; or daratumumab and dexamethasone; or daratumumab and hyaluronidase-fihj and dexamethasone. It is also indicated as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy.[L39392] |
| Marketing Status |
approved; investigational |
| ATC Code |
L01XG02 |
| DrugBank ID |
DB08889
|
| KEGG ID |
D08880
|
| MeSH ID |
C524865
|
| PubChem ID |
11556711
|
| TTD Drug ID |
D00UVA
|
| NDC Product Code |
76055-0035; 76075-103; 76075-101; 63552-009; 67262-0010; 42385-731; 76075-102; 63552-035; 54893-0037; 52076-6251; 55111-985; 11722-059 |
| UNII |
72X6E3J5AR
|
| Synonyms |
carfilzomib | PR-171 | PR171 | Kyprolis |
|
| Chemical Information |
| Molecular Formula |
C40H57N5O7 |
| CAS Registry Number |
868540-17-4 |
| SMILES |
CC(C)CC(C(=O)C1(CO1)C)NC(=O)C(CC2=CC=CC=C2)NC(=O)C(CC(C)C)NC(=O)C(CCC3=CC=CC=C3)
NC(=O)CN4CCOCC4 |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|
| ADR Term |
ADReCS ID |
ADR Frequency (FAERS)
|
ADR Severity Grade (FAERS)
|
ADR Severity Grade (CTCAE)
|
|
|
|
